KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma
Keywords: Acral lentiginous melanoma; KIT; NRAS; BRAF; PTEN
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Molecular Diagnostics in the Neoplasms of Small Intestine and Appendix
Keywords: Microsatellite instability; KRAS; BRAF; Small intestine; Appendix;
Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications
Keywords: Autophagy, Melanoma; Tumorigenesis; BRAF; Chemoresistance
TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type
Keywords: Epithelial ovarian cancer; Deep-sequencing; TP53; KRAS; BRAF
B-Raf mutation: A key player in molecular biology of cancer
Keywords: B-Raf; BRAF; Mutation; Melanoma; Colorectal cancer; Thyroid cancer
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAFV600E: A non-invasive tool panel for early detection of thyroid cancer
Keywords: Cell-free-DNA; Thyroid cancers; Methylation; BRAF; Early diagnosis
Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma
Keywords: Papillary; Thyroid; Carcinoma; EGFR; BRAF; Molecular; Immunohistochemistry
Fibroblast-mediated drug resistance in cancer
Keywords: Melanoma; Fibroblasts; BRAF; Stroma; ECM
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
Keywords: Non-small cell lung cancer; Targeted therapy; Third-line therapy; Tyrosine kinase inhibitor; Multikinase inhibitor; Epidermal growth factor receptor; Vascular endothelial growth factor receptor; RAF/MEK/ERK; BRAF
Carcinoma colorrectal serrado: caracterización morfológica, inmunohistoquímica y molecular
Keywords: Carcinoma colorrectal; Carcinoma serrado; Gemación tumoral; Inestabilidad de microsatélites; KRAS; BRAFColorectal carcinoma; Serrated carcinoma; Microsatellite instability; Tumor budding; KRAS; BRAF
Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases : Report of 3 cases, with morphological and molecular analysis
Keywords: Microcarcinoma; Papillary thyroid carcinoma; Tall cell variant; BRAF; Fatal outcome
Melanoma
Keywords: Melanoma; Skin cancer; BRAF; Immunotherapy; Noninvasive imaging;
Personalized Oncology in Interventional Radiology
Keywords: ATP; adenosine triphosphate; ALK; analplastic lymphoma factor; BCR-ABL; breakpoint cluster region/the Abelson tyrosine; BRAF; v-raf murine sarcoma viral oncogene; CD-20; clusters of differentiation-20 (antigen of B-cells); c-KIT; tyrosine-protein kinase k
V600EBRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism
Keywords: BRAF; Snail; E-cadherin; EMT; Invasion; Thyroid cancer
Genetics and pharmacogenomics of diffuse gliomas
Keywords: Companion diagnostics; Glioma; 1p/19q co-deletion; IDH1; Pharmacogenomics; EGFRvIII; CGH; comparative genomic hybridization; CNA; copy number aberrations; CRC; colorectal carcinoma; CML; chronic myeloid leukemia; EGFR; epidermal growth factor receptor; FF
Effets indésirables cutanés des inhibiteurs de BRAFÂ : revue systématique
Keywords: Vemurafenib; Dabrafenib; BRAF; Mélanome; Effets indésirables cutanés; Vemurafenib; Dabrafenib; BRAF; Malignant melanoma; Dermatologic adverse events;
Erdheim-Chester Disease
Keywords: Erdheim-Chester disease; Histiocytosis; Langerhans cell histiocytosis; Interferon α; BRAF;
Applications and limitations of oncogene mutation testing in clinical cytopathology
Keywords: Cytology; Aspiration; PCR; c-KIT; BRAF; EGFR; KRAS; NRAS
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
Keywords: Prognostic factor; Predictive factor; Molecular marker; Epidermal growth factor receptor (EGFR) inhibitors; KRAS; BRAF; PIK3CA; PTEN
Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma
Keywords: BRAF; drug reaction; follicular hyperkeratosis; metastatic melanoma; retinoids; vemurafenibHFSR, hand-foot skin reaction; KA, keratoacanthomas; KP, keratosis pilaris; MAPK, mitogen-activated protein kinase; SCC, squamous cell carcinomas
Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research
Keywords: PLX4720; PLX4032; BRAF; MAOS; Melanoma;
Melanocytic Tumour in a Black Sheep never exposed to Ultraviolet Radiation
Keywords: BRAF; GNAQ; melanocytic tumour; sheep
Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents
Keywords: BRAF; V-RAF murine sarcoma viral oncogene homologue B1; pERK; phosphorylated extracellular regulated kinase; BRAFV600E; V600E mutant BRAF; BRAFWT; BRAF wild-type; IC50; half maximal inhibitory concentration; GI50; the concentration that causes 50% growth
Emerging therapies for thyroid carcinoma
Keywords: Thyroid carcinoma; Tyrosine kinase inhibitors; Papillary; Medullary; Anaplastic; BRAF; RET; Vandetanib; Sunitinib; Sorafenib; Imatinib; Motesanib
BRAF Mutations in Metanephric Adenoma of the Kidney
Keywords: Small renal mass; Diagnosis; BRAF; Mutation; Metanephric adenoma
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples
Keywords: CAST-PCR; KRAS; BRAF; EGFR; Mutation; Targeted therapy
Molecular biology of melanoma
Keywords: BRAF; KIT; melanoma; melanoma mutations; mitogen-activated protein kinase; RASCDK, cyclin-dependent kinase; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3’-kinase; PTEN, phosphatase with tensin homolog
KRAS and BRAF mutations in sinonasal cancer
Keywords: Maxillary sinus; Ethmoid sinus; Sinonasal; Squamous cell carcinoma; Adenocarcinoma; KRAS; BRAF
BRAFV600E mutation analysis of liquid-based preparation–processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma
Keywords: Liquid-based preparation of cytology specimens; BRAF; Thyroid; Papillary carcinoma
c-kit gene mutation and CD117 expression in human anorectal melanomas
Keywords: c-kit Mutation; Anorectal; Melanoma; BRAF; CD117
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Keywords: Melanoma; BRAF; NRAS; Mutation; Overall survival
Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors
Keywords: BRAF; Mutant; Inhibitors; Melanoma; Virtual screeningBRAFhomolog B1, V-RAF murine sarcoma viral oncogene; pERK, phosphorylated extracellular regulated kinase; BRAFV600E, V600E mutant BRAF; BRAFWT, BRAF wild-type; IC50, half maximal inhibitory concentratio
Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma
Keywords: BRAF; Colorectal cancer; Biopsy; KRAS; Molecular pathology;
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
Keywords: acantholytic dyskeratosis; BRAF; drug adverse effects; nevi; squamous cell carcinoma; verrucous keratosis; warty dyskeratomaCFC, cardiofaciocutaneous; KA, keratoacanthoma; MAPK, mitogen-activated protein kinase; SCC, squamous cell carcinoma
Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors
Keywords: BRAF; V-RAF murine sarcoma viral oncogene homolog B1; BRAFV600E; V600E mutant BRAF; IC50; half maximal inhibitory concentration; GI50; the concentration that causes 50% growth inhibition; 3D-QSAR; quantitative structure-activity relationship; Synthesis;
Association of galectin-3 expression with melanoma progression and prognosis
Keywords: Melanoma; Galectin-3; Prognosis; BRAF;
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma
Keywords: Ovarian clear cell carcinoma; PIK3CA; KRAS; BRAF; Mutation
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Keywords: Cetuximab; KRAS; BRAF; Colorectal cancer;
Molecular typing of colorectal cancer: applications in diagnosis and treatment
Keywords: BRAF; cancer; colorectal; KRAS; Lynch; microsatellite instability;
New Therapeutic Targets in Melanoma
Keywords: Melanoma; Therapeutic targets; Molecular targets; BRAF; C-kit; Anti CTLA-4Melanoma; Dianas terapéuticas; Dianas moleculares; BRAF; C-Kit; Anti CTLA-4
Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
Keywords: BRAF; MEK/ERK; Melanoma; Apoptosis; PI3K/AKT/mTOR
Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
Keywords: BRAF; malignant melanoma; PLX4032; vemurafenib
Management of Pigmented Conjunctival Lesions
Keywords: BRAF; complexion-associated melanosis; conjunctival melanosis; genetics; melanoma; nevus; no-touch surgery; ocular surface; pigmented lesion; primary acquired melanosis (PAM); topical chemotherapy
Sorafénib et radiothérapie dans le carcinome hépatocellulaire
Keywords: Carcinome hépato-cellulaire; Sorafénib; Radiothérapie; VEGF; ERK; Traitement; BRAFHepatocellular carcinoma; Sorafenib; Radiotherapy; VEGF; BRAF; ERK; Treatment
Cardio-facio-cutaneous syndrome with infantile spasms and delayed myelination
Keywords: Cardio-facio-cutaneous syndrome; Infantile spasms; BRAF; Abnormal myelination
KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients
Keywords: KRAS; BRAF; PIK3CA; Biliary tract cancer
Pathology of malignant skin tumours
Keywords: Angiosarcoma; appendage tumours; atypical fibroxanthoma; basal cell carcinoma; BRAF; c-Kit; dermatofibrosarcoma protuberans; lymphoma; melanoma; Merkel cell carcinoma; molecular genetics; squamous cell carcinoma;
Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue
Keywords: KRAS; BRAF; PIK3CA; Colorectal cancer; Peptide nucleic acids; Mutation
KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer
Keywords: BRAF; Cetuximab; Chemoradiotherapy; KRAS; PTEN;
Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?
Keywords: BRAF; Epidermal growth factor receptor; KRAS; PTEN